Try our Advanced Search for more refined results

Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc.

  1. February 15, 2022

    Fed. Circ. Says 'Ad Hoc' Group Can't Revive Amarin Drug IP

    A Federal Circuit panel on Tuesday quickly shut down an effort by a self-described "ad hoc" group of Amarin Pharma Inc. shareholders to challenge a Nevada federal judge's decision to throw out six patents on Amarin's blockbuster heart drug Vascepa.

  2. February 11, 2022

    Fed. Circ. Doubts 'Ad Hoc' Group Can Revive Amarin Drug IP

    A Federal Circuit panel expressed skepticism Friday that a self-described "ad hoc" group that includes Amarin Pharma Inc. shareholders has standing to intervene to challenge a Nevada federal judge's invalidation of six patents on Amarin's blockbuster heart drug Vascepa.

  3. February 03, 2022

    IP Forecast: 11th Circ. To Eye Biz's $20M Trade Secrets Loss

    The Eleventh Circuit next week will consider arguments from owners of a defunct South Florida drug treatment center to wipe out a nearly $20 million verdict against them after a jury found they stole trade secrets from an electronic medical records provider. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.